ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Covid19 Antibody was a Fraud

<< Previous

Bullboard Posts

Next >>

Comment by M101on Mar 27, 2022 1:58pm

89 Views

Post# 34549895

RE:RE:RE:Covid19 Antibody was a Fraud

Another one of your hunches?
I love a good conspiracy theory, please go on!

This was DOA when arrival became a deal with a bunch of homeopaths, presumably the only deal available for the obvious reason that no other market ever developed for a service that was neither fast nor cheap.

But if you've found some evidence that Promis wasted more resources on this venture than revealed please post it.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale